ReViral Ltd, a developer of antiviral compounds to treat respiratory syncytial virus (RSV), has named Alex C. Sapir as chief executive, replacing Eddy Littler who assumes the post of chief operating officer. Mr Sapir, who holds a bachelor’s degree from Franklin and Marshall College in Lancaster, Pennsylvania, and a master’s degree from Harvard Business School, both US previously was chairman and CEO of Dova Pharmaceuticals Inc, which specialises in acquiring, developing, and commercialising drug candidates for thrombocytopenia disease.
ReViral announced the appointment on 11 June 2019.
Copyright 2019 Evernow Publishing Ltd